Jump to content

Oral submucous fibrosis

From Wikipedia, the free encyclopedia
(Redirected from Submucous fibrosis)

Oral submucous fibrosis
Other namesOSMF or OSF
SpecialtyOral medicine and Dentistry and Oral Pathology

Oral submucous fibrosis (OSF) is a chronic, complex, premalignant (1% transformation risk) condition of the oral cavity, characterized by juxta-epithelial inflammatory reaction and progressive fibrosis of the submucosal tissues (the lamina propria and deeper connective tissues). As the disease progresses, the oral mucosa becomes fibrotic to the point that the person is unable to open the mouth.[1][2] The condition is remotely linked to oral cancers and is associated with the chewing of areca nut and/or its byproducts, commonly practiced in South and South-East Asian countries.[3] The incidence of OSF has also increased in western countries due to changing habits and population migration.[4]

Definitions

[edit]
  • Per Jens J. Pindborg and Satyavati Sirsat (1966, pathological definition): 'An insidious chronic disease affecting any part of the oral cavity and sometimes the pharynx. Although occasionally preceded by and/or associated with vesicle formation, it is always associated with a juxta-epithelial inflammatory reaction followed by a fibro-elastic change of the lamina propria, with epithelial atrophy leading to stiffness.'[5]
  • Per Mohit Sharma and Raghu Radhakrishnan (2019): 'An insidious, chronic potentially malignant fibrotic disorder affecting the entire oral cavity and sometimes the pharynx and oesophagus. Although occasionally preceded by and/or associated with vesicle formation, it is always associated with a juxta-epithelial inflammatory reaction followed by a fibroelastic change of the lamina propria with epithelial atrophy leading to stiffness of the oral mucosa, progressive decrement in mouth opening and inability to eat'[6]
  • Per Chandramani More and Naman Rao (2019, clinical definition): 'A debilitating, progressive, irreversible collagen metabolic disorder induced by chronic chewing of areca nut and its commercial preparations; affecting the oral mucosa and occasionally the pharynx and esophagus; leading to mucosal stiffness and functional morbidity; and has a potential risk of malignant transformation.'[7]
  • Per Sharma et al., in 2024 redefined it OSF as “Areca nut-induced potentially malignant disorder of the oral mucosal tissues, pharynx, and esophagus characterized by fibrosis akin to an overhealing wound, leading to progressive reduction in mouth opening.”[8]

Symptoms

[edit]

In the initial phase of the disease, the mucosa feels leathery with palpable fibrotic bands. The oral mucosa loses resiliency in the advanced stage and becomes blanched and stiff. This blanched and stiff mucosa is considered to lead to a progressive reduction in mouth opening but seems to be an oversimplification of the pathology. The degree of mouth opening is also determined by the severity of oral symptoms, such as recurring or persistent glossitis and stomatitis, a fact that many researchers ignore. This phenomenon is explained by the term Reflectory Trismus, where the above symptoms dictate the degree of mouth opening through activation of the 5th and 9th cranial nerves. However, muscle damage and fibrosis play a larger contributory role.[9] The condition is believed to begin in the posterior part of the oral cavity and gradually spread outward. The premise posterior to the anterior progression of oral submucous fibrosis has been recently rebutted based on several reports stating that the disease may be restricted to the anterior part of the oral cavity without involvement of posterior parts; the sites are dictated by the manner of use anterior areas of the oral cavity when spitting and posterior when swallowed.[10]

Other features of the disease include:

  • Xerostomia
  • Recurrent ulceration
  • Pain in the ear or deafness
  • Nasal intonation of voice
  • Restriction of the movement of the soft palate
  • A budlike shrunken uvula
  • Thinning and stiffening of the lips
  • Pigmentation of the oral mucosa
  • Dryness of the mouth and burning sensation (stomatopyrosis)
  • Decreased tongue protrusion

Cause

[edit]
  • Dried products such as paan masala and gutkha have higher concentrations of areca nut and appear to cause the disease.
  • Areca nut is the definitive causative agent of OSF.[8]
  • A new term was introduced by Sharma et al., in 2024 "Areca Nut induced Oral Fibrosis (AIOF)" since fibrosis in the oral cavity can occur due to various causes and thus have varying malignant propensity. The reclassification of OSF as AIOF has significant implications for diagnosis and management. It emphasizes the primary causative agent and its role in developing the condition. This reclassification improves diagnosis, management, and patient education. Recognizing AIOF as a distinct entity also enhances understanding, enables researchers to explore prevention strategies, and equips policymakers to implement targeted public health campaigns.[8]
  • Fibrosis due to other causes has distinctive features and should be named according to cause and not called oral submucous fibrosis [8]
    • Immunological diseases can occur in the background of graft vs Host Disease or as an oral manifestation of systemic sclerosis[8]
    • Khat Induced Oral fibrosis[8]
    • Oral fibrosis due to Iron defiency anemia
    • Tobacco-induced oral fibrosis[8]

Pathogenesis

[edit]

"Exposure to areca nut (Areca catechu) containing products with or without tobacco (ANCP/T) is currently believed to lead to OSF in individuals with genetic immunologic or nutritional predisposition to the disease.".[11] On the other hand, reduced CD1a+ Langerhans cells and CD207+ dendritic cells indicate evolving immunosuppression in OSF and its progression to OSCC.[12]

This hypersensitivity reaction results in a juxta-epithelial inflammation that leads to increased fibroblastic activity and decreased breakdown of fibers. The fibroblasts are phenotypically modified, and the fibers they form are more stable, produce thicker bundles that progressively become less elastic. once the original loosely arranged fibrous tissue is replaced by the ongoing fibrosis, the movability of the oral tissues is reduced, there is loss of flexibility and reduced opening of the mouth. These collagen fibers are non degradable and the phagocytic activity is minimized. The role of pure capsaicin in the etiology and pathogenesis of oral submucous fibrosis has been debunked, as its has been shown to have antifibrotic and anticancer effects.[13] Mosqueda-Solís in their Systematic review have shown anticancer activity of capsaicin on oral cancer.[14] It has been shown by computational biology, capsaicin hinders the collagen fibre formation.[13] Moreover, capsaicin has been shown to cause the degradation of collagen I by activation of MMP1 through TRPV1 channels.[15]

According to a 2015 cross-sectional study, the time taken for return of salivary pH to baseline levels after chewing areca-nut-containing mixtures is significantly longer in habitual users with OSF when compared to unaffected users.[11] Prolonged alkaline pH induces death of the fetal fibroblast type and replacement by a profibrotic fibroblast.[11] The patterns of intraoral fibrotic bands produced by alkaline chemical injury mimic those produced by areca nut chewing.[16] Sharma et al. have equated the pathogenesis of OSF to an over-healing wound, to explain its evolution as well as malignant transformation.[16][17] Given that OSF is an overhealing wound, Choudhari et al. have recently implicated that factor XIIIa (the last factor in the coagulation pathway) plays a critical role in the development of fibrosis in OSF and that there is a strong correlation between factor XIIIa and increasing grades of OSF in their study.[18] Incidentally, Sharma et al. in 2018 had already proposed an important role of factor XIIIa in the pathogenesis of OSF, by promoting the generation of fibrin degradation products (FDP).[16] Literature is replete with patients with OSF having FDPs in their blood, and this can be considered as a proof for the role of factor XIIIa in the pathogenesis of OSF.[16]

Increased mechanical stiffness through YAP/TAZ pathway accelerates the malignant transformation of OSF.[19] The atrophic epithelium in OSF has been attributed to the senescence of the basal stem cell layer and the development of hyperplastic epithelium through senescence escape.[17][20] The role of senescence in pathogenesis of oral submucous fibrosis has been supported by further research.[21][22][23]

Diagnosis

[edit]

Classification

[edit]

Oral submucous fibrosis is clinically divided into three stages:[24]

  • Stage 1: Stomatitis
  • Stage 2: Fibrosis
    • a. Early lesions, blanching of the oral mucosa
    • b. Older lesions, vertical and circular palpable fibrous bands in and around the mouth or lips, resulting in a mottled, marble-like appearance of the buccal mucosa
  • Stage 3: Sequelae of oral submucous fibrosis

Khanna and Andrade in 1995 developed a group classification system for the surgical management of trismus:[25]

  • Group I: Earliest stage without mouth opening limitations with an interincisal distance of greater than 35 mm.
  • Group II: Patients with an interincisal distance of 26–35 mm.
  • Group III: Moderately advanced cases with an interincisal distance of 15–26 mm. Fibrotic bands are visible at the soft palate, and pterygomandibular raphe and anterior pillars of fauces are present.
  • Group IVA: Trismus is severe, with an interincisal distance of less than 15 mm and extensive fibrosis of all the oral mucosa.
  • Group IVB: Disease is most advanced, with premalignant and malignant changes throughout the mucosa. Tumor necrosis factor alpha and keratin 17 are interdependent regulators; they could be used as diagnostic markers and a prognostic mirror of oral submucous fibrosis cases[26]

Treatment

[edit]

Biopsy screening, although necessary, is not mandatory; most dentists can visually examine the area and proceed with the proper course of treatment.[citation needed]

Treatment includes:

  • Abstention from chewing areca nut (also known as betel nut) and tobacco
  • Minimizing consumption of spicy foods, including chiles
  • Maintaining proper oral hygiene
  • Supplementing the diet with foods rich in vitamins A, B complex, and C and iron
  • Forgoing hot fluids like tea, coffee
  • Forgoing alcohol
  • Employing a dental surgeon to round off sharp teeth and extract third molars
  • Interprofessional treatment approach[27]

Treatment also includes following:

  • The prescription of chewable pellets of hydrocortisone (Efcorlin); one pellet to be chewed every three to four hours for three to four weeks
  • 0.5 ml intralesional injection Hyaluronidase 1500 IU mixed in 1 ml of Lignocaine into each buccal mucosa once a week for 4 weeks or more as per condition
  • 0.5 ml intralesional injection of Hyaluronidase 1500 IU and 0.5 ml of injection Hydrocortisone acetate 25 mg/ml in each buccal mucosa once a week alternatively for 4 weeks or more as per condition[28]
  • Submucosal injections of hydrocortisone 100 mg once or twice daily depending upon the severity of the disease for two to three weeks
  • Submucosal injections of human chorionic gonadotrophins (Placentrax) 2–3 ml per sitting twice or thrice in a week for three to four weeks
  • Surgical treatment is recommended in cases of progressive fibrosis when interincisor distance becomes less than 2 centimetres (0.79 in). (Multiple release incisions deep to mucosa, submucosa and fibrotic tissue and suturing the gap or dehiscence so created by mucosal graft obtained from tongue and Z-plasty. In this procedure multiple deep z-shaped incisions are made into fibrotic tissue and then sutured in a straighter fashion.)
  • Pentoxifylline (Trental), a methylxanthine derivative that has vasodilating properties and increases mucosal vascularity, is also recommended as an adjunct therapy in the routine management of oral submucous fibrosis.[29]
  • IFN-gamma is an antifibrotic cytokine which alters collagen synthesis and helps in OSF.[30]
  • Colchicine tablets 0.5 mg twice a day[31]
  • Lycopene, 16 mg a day helps in improvement of OSF[32]

The treatment of patients with oral submucous fibrosis depends on the degree of clinical involvement.[33] If the disease is detected at a very early stage, cessation of the habit is sufficient. Most patients with oral submucous fibrosis present with moderate-to-severe disease. Severe oral submucous fibrosis is irreversible. Moderate oral submucous fibrosis is reversible with cessation of habit and mouth opening exercise. Current modern day medical treatments can make the mouth opening to normal minimum levels of 30 mm mouth opening with proper treatment.

Research

[edit]

Scientists have proven that intralesional injection of autologous bone marrow stem cells is a safe and effective treatment modality in oral submucosal fibrosis. It has been shown autologous bone marrow stem cell injections induces angiogenesis in the lesion area, which in turn decreases the extent of fibrosis, thereby leading to significant increase in mouth opening.[34][35]

Epidemiology

[edit]

The incidence of the disease is higher in people from certain parts of the world including South and South East Asian, South Africa and the Middle Eastern countries.[36] In 1996, the number of cases were estimated around 2.5 million worldwide but there is no population-base data as it is not notifiable disease. In India, the prevalence is estimated 0.2–2.3% in males and 1.2–4.6% in females; with age range of 11 to 60 years. It is widely reported in South Asian diaspora in Europe, North America and South Africa.[37]

History

[edit]

In 1952, T. Sheikh coined the term distrophica idiopathica mucosa oris to describe an oral fibrosing disease he discovered in five Indian women from Kenya.[38] S. G. Joshi subsequently coined the termed oral submucous fibrosis (OSF) for the condition in 1953.[39]

See also

[edit]

References

[edit]
  1. ^ Cox SC, Walker DM (October 1996). "Oral submucous fibrosis. A review". Australian Dental Journal. 41 (5): 294–299. doi:10.1111/j.1834-7819.1996.tb03136.x. PMID 8961601.
  2. ^ Aziz SR (1997). "Oral submucous fibrosis: an unusual disease". Journal of the New Jersey Dental Association. 68 (2): 17–19. PMID 9540735.
  3. ^ More CB, Rao NR, More S, Johnson NW (2020). "Reasons for Initiation of Areca Nut and Related Products in Patients with Oral Submucous Fibrosis within an Endemic Area in Gujarat, India". Substance Use & Misuse. 55 (9): 1413–1421. doi:10.1080/10826084.2019.1660678. PMID 32569538. S2CID 219991434.
  4. ^ More C, Shah P, Rao N, Pawar R (2015). "Oral Submucous Fibrosis: An Overview with Evidence Based Management". International Journal of Oral Health Sciences and Advances. 3 (3): 40–9.
  5. ^ Pindborg JJ, Sirsat SM (December 1966). "Oral submucous fibrosis". Oral Surgery, Oral Medicine, and Oral Pathology. 22 (6): 764–779. doi:10.1016/0030-4220(66)90367-7. PMID 5224185. S2CID 39879726.
  6. ^ Sharma M, Radhakrishnan R (May 2019). "Revisiting and revising the definition of oral submucous fibrosis". Oral Oncology. 92: 94. doi:10.1016/j.oraloncology.2019.03.004. PMID 30853277. S2CID 73727899.
  7. ^ More CB, Rao NR (2019). "Proposed clinical definition for oral submucous fibrosis". Journal of Oral Biology and Craniofacial Research. 9 (4): 311–314. doi:10.1016/j.jobcr.2019.06.016. PMC 6614531. PMID 31334003.
  8. ^ a b c d e f g Sharma M, Sarode SC, Sarode G, Radhakrishnan R (February 2024). "Areca nut-induced oral fibrosis - Reassessing the biology of oral submucous fibrosis". Journal of Oral Biosciences. 66 (2): 320–328. doi:10.1016/j.job.2024.02.005. PMID 38395254.
  9. ^ Sharma M, Radhakrishnan R. Limited mouth opening in oral submucous fibrosis: reasons, ramifications, and remedies. J Oral Pathol Med. 2017 Jul;46(6):424-430. doi: 10.1111/jop.12513. Epub 2016 Nov 4. PMID 27743497.
  10. ^ Sharma M, Radhakrishnan R (June 2023). "Should oral submucous fibrosis be restaged?". Oral Oncology Reports. 6: 100049. doi:10.1016/j.oor.2023.100049.
  11. ^ a b c Donoghue M, Basandi PS, Adarsh H, Madhushankari GS, Selvamani M, Nayak P (2015). "Habit-associated salivary pH changes in oral submucous fibrosis-A controlled cross-sectional study". Journal of Oral and Maxillofacial Pathology. 19 (2): 175–181. doi:10.4103/0973-029X.164529. PMC 4611925. PMID 26604493.
  12. ^ Silva LC, Fonseca FP, Almeida OP, Mariz BA, Lopes MA, Radhakrishnan R, et al. (January 2020). "CD1a+ and CD207+ cells are reduced in oral submucous fibrosis and oral squamous cell carcinoma". Medicina Oral, Patologia Oral y Cirugia Bucal. 25 (1): e49 – e55. doi:10.4317/medoral.23177. PMC 6982989. PMID 31880289.
  13. ^ a b Huang Z, Sharma M, Dave A, Yang Y, Chen ZS, Radhakrishnan R (2022). "The Antifibrotic and the Anticarcinogenic Activity of Capsaicin in Hot Chili Pepper in Relation to Oral Submucous Fibrosis". Frontiers in Pharmacology. 13: 888280. doi:10.3389/fphar.2022.888280. PMC 9114457. PMID 35600864.
  14. ^ Mosqueda-Solís A, Lafuente-Ibáñez de Mendoza I, Aguirre-Urizar JM, Mosqueda-Taylor A (2021). "Capsaicin intake and oral carcinogenesis: A systematic review". Med Oral Patol Oral Cir Bucal. 26 (2): e261-8. doi:10.4317/medoral.24570. PMC 7980287. PMID 33609025.
  15. ^ Xiao T, Sun M, Zhao C, Kang J (2023). "TRPV1: A promising therapeutic target for skin aging and inflammatory skin diseases". Frontiers in Pharmacology. 14: 1037925. doi:10.3389/fphar.2023.1037925. PMC 9975512. PMID 36874007.
  16. ^ a b c d Sharma M, Shetty SS, Radhakrishnan R (2018-07-31). "Oral Submucous Fibrosis as an Overhealing Wound: Implications in Malignant Transformation". Recent Patents on Anti-Cancer Drug Discovery. 13 (3): 272–291. doi:10.2174/1574892813666180227103147. PMID 29485009. S2CID 3583422.
  17. ^ a b Sharma M, Fonseca FP, Hunter KD, Radhakrishnan R (August 2020). "Loss of oral mucosal stem cell markers in oral submucous fibrosis and their reactivation in malignant transformation". International Journal of Oral Science. 12 (1): 23. doi:10.1038/s41368-020-00090-5. PMC 7442837. PMID 32826859.
  18. ^ Choudhari S, Kulkarni D, Patankar S, Kheur S, Sarode S (2024). "Linking inflammation and angiogenesis with fibrogenesis: Expression of FXIIIA, MMP-9, and VEGF in oral submucous fibrosis". Revista Espanola de Patologia. 57 (1): 15–26. doi:10.1016/j.patol.2023.11.005. PMID 38246706. S2CID 266702966.
  19. ^ Sharma M, Hunter KD, Fonseca FP, Shetty SS, Radhakrishnan R (August 2021). "Role of Yes-associated protein and transcriptional coactivator with PDZ-binding motif in the malignant transformation of oral submucous fibrosis". Archives of Oral Biology. 128: 105164. doi:10.1016/j.archoralbio.2021.105164. PMID 34044344. S2CID 235232425.
  20. ^ Sharma M, Hunter KD, Fonseca FP, Radhakrishnan R (October 2021). "Emerging role of cellular senescence in the pathogenesis of oral submucous fibrosis and its malignant transformation". Head & Neck. 43 (10): 3153–3164. doi:10.1002/hed.26805. PMID 34227702. S2CID 235743764.
  21. ^ Bijai LK, Muthukrishnan A (April 2022). "Potential role of fibroblast senescence in malignant transformation of oral submucous fibrosis". Oral Oncology. 127: 105810. doi:10.1016/j.oraloncology.2022.105810. PMID 35303624. S2CID 247495941.
  22. ^ Zhang P, Chua NQ, Dang S, Davis A, Chong KW, Prime SS, et al. (January 2022). "Molecular Mechanisms of Malignant Transformation of Oral Submucous Fibrosis by Different Betel Quid Constituents-Does Fibroblast Senescence Play a Role?". International Journal of Molecular Sciences. 23 (3): 1637. doi:10.3390/ijms23031637. PMC 8836171. PMID 35163557.
  23. ^ Karnam S, Girish HC, Nayak VN (2022). "Senescent Fibroblast in Oral Submucous Fibrosis Aids in Disease Progression and Malignant Transformation". Journal of Oral and Maxillofacial Pathology. 26 (2): 199–207. doi:10.4103/jomfp.jomfp_115_21. PMC 9364628. PMID 35968184.
  24. ^ Pindborg JJ (September 1989). "Oral submucous fibrosis: a review". Annals of the Academy of Medicine, Singapore. 18 (5): 603–607. PMID 2694917.
  25. ^ Khanna JN, Andrade NN (December 1995). "Oral submucous fibrosis: a new concept in surgical management. Report of 100 cases". International Journal of Oral and Maxillofacial Surgery. 24 (6): 433–439. doi:10.1016/S0901-5027(05)80473-4. PMID 8636640.
  26. ^ Abd El Latif GA (January 2019). "Tumor necrosis factor alpha and keratin 17 expression in oral submucous fibrosis in rat model". Egyptian Dental Journal. 65 (1 (Oral Medicine, X–Ray, Oral Biology & Oral Pathology) pages - 277–88): 277–288. doi:10.21608/edj.2015.71414.
  27. ^ Rao NR, Villa A, More CB, Jayasinghe RD, Kerr AR, Johnson NW (January 2020). "Oral submucous fibrosis: a contemporary narrative review with a proposed inter-professional approach for an early diagnosis and clinical management". Journal of Otolaryngology–Head & Neck Surgery. 49 (1): 3. doi:10.1186/s40463-020-0399-7. PMC 6951010. PMID 31915073.
  28. ^ Kakar PK, Puri RK, Venkatachalam VP (January 1985). "Oral submucous fibrosis--treatment with hyalase". The Journal of Laryngology and Otology. 99 (1): 57–59. doi:10.1017/S0022215100096286. PMID 3968475. S2CID 45613554.
  29. ^ Rajendran R, Rani V, Shaikh S (2006). "Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis". Indian Journal of Dental Research. 17 (4): 190–198. doi:10.4103/0970-9290.29865. PMID 17217216.
  30. ^ Haque MF, Meghji S, Nazir R, Harris M (January 2001). "Interferon gamma (IFN-gamma) may reverse oral submucous fibrosis". Journal of Oral Pathology & Medicine. 30 (1): 12–21. doi:10.1034/j.1600-0714.2001.300103.x. PMID 11140895.
  31. ^ Krishnamoorthy B, Khan M (July 2013). "Management of oral submucous fibrosis by two different drug regimens: A comparative study". Dental Research Journal. 10 (4): 527–532. PMC 3793419. PMID 24130591.
  32. ^ Kumar A, Bagewadi A, Keluskar V, Singh M (February 2007). "Efficacy of lycopene in the management of oral submucous fibrosis". Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics. 103 (2): 207–213. doi:10.1016/j.tripleo.2006.07.011. PMID 17234537.
  33. ^ More CB, Gavli N, Chen Y, Rao NR (2018). "A novel clinical protocol for therapeutic intervention in oral submucous fibrosis: An evidence based approach". Journal of Oral and Maxillofacial Pathology. 22 (3): 382–391. doi:10.4103/jomfp.JOMFP_223_18. PMC 6306594. PMID 30651684.
  34. ^ Sankaranarayanan S, Padmanaban J, Ramachandran CR, Manjunath S, Baskar S, Senthil Kumar R, et al. (June 2008). Autologous Bone Marrow stem cells for treatment of Oral Sub-Mucous Fibrosis - a case report. Sixth Annual Meeting of International Society for Stem Cell Research (ISSCR). Philadelphia.
  35. ^ Abraham S, Sankaranarayanan S, Padmanaban J, Manimaran K, Srinivasan V, Senthil Nagarajan R, et al. (June 2008). Autologous Bone Marrow Stem Cells in Oral Submucous Fibrosis – Our experience in three cases with six months follow-up. 8th Annual Meeting of Japanese Society of Regenerative Medicine. Vol. 68. Tokyo, Japan. pp. 233–55.
  36. ^ Oral Submucous Fibrosis at eMedicine
  37. ^ Rao NR, Villa A, More CB, Jayasinghe RD, Kerr AR, Johnson NW (2020-01-01). "Oral submucous fibrosis: A contemporary narrative review with a proposed inter-professional approach for an early diagnosis and clinical management". Journal of Otolaryngology - Head & Neck Surgery. 49 (1): 3. doi:10.1186/s40463-020-0399-7. ISSN 1916-0216. PMC 6951010. PMID 31915073.
  38. ^ Hetland G, Johnson E, Lyberg T, Bernardshaw S, Tryggestad AM, Grinde B (October 2008). "Effects of the medicinal mushroom Agaricus blazei Murill on immunity, infection and cancer". Scandinavian Journal of Immunology. 68 (4): 363–370. doi:10.1111/j.1365-3083.2008.02156.x. PMID 18782264.
  39. ^ Joshi SG (1952). "Fibrosis of the palate and pillars". Indian Journal of Otolaryngology. 4 (1): 1–4.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Oral_submucous_fibrosis&oldid=1260095626"